Cost‑effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non‑Muscle Invasive Bladder Cancer patients (NMIBC) in Italy

Craig Bennison, Stephanie Stephens, Giario Natale Conti

DOI: https://doi.org/10.7175/fe.v15i3.944

Abstract

OBJECTIVE: To estimate the incremental cost‑effectiveness of hexaminolevulinate (Hexvix®) + Blue Light (H+BL) cystoscopy (compared to white light cystoscopy only) when used at initial transurethral resection of the bladder tumour (TURBT) for patients diagnosed with non‑muscle invasive bladder cancer (NMIBC) in Italy.
METHODS: A cost‑effectiveness model has been developed to estimate the incremental cost‑effectiveness of introducing H+BL at initial TURBT for patients diagnosed with NMIBC in Italy. The model consists of two parts: 1) a short term decision tree which estimates the outcome of the initial diagnostic procedure, and 2) a Markov cohort model which is used to estimate long term outcomes through extrapolation based on data and assumptions about patient management, the natural history of the disease and the empirical efficacy of H+BL in improving diagnosis detection and reducing recurrence. Cost‑effectiveness results are expressed as incremental costs per QALY gained. Univariate and probabilistic sensitivity analyses are conducted to test the robustness of the model to changes in inputs and assumptions.
RESULTS: Base case results suggest that Hexvix® is a dominant strategy when used in the resection of NMIBC. Hexvix® is expected to be associated with 0.070 incremental QALYs, with cost savings of € 435 per patient. Sensitivity analyses suggest that the cost of Hexvix® and the relative risk of recurrence in intermediate and low risk groups are key drivers in the model. Probabilistic analyses indicate that Hexvix® is expected to be cost‑effective in >99% of iterations, assuming a willingness to pay threshold of € 25,000 per QALY.
CONCLUSION: In conclusion, Hexvix® is expected to be a cost‑effective strategy when used in the resection of NMIBC in Italy.

 

Keywords

Cost‑effectiveness; Hexvix®; Cystoscopy; NMIBC

Full Text:

HTML PDF

References

  • Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010; 14: 1-331; http://dx.doi.org/10.3310/hta14040
  • Malmström PU, Hedelin H, Thomas YK, et al. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009; 43: 192-8; http://dx.doi.org/10.1080/00365590902808541
  • Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64: 639-53; http://dx.doi.org/10.1016/j.eururo.2013.06.003
  • WHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence worldwide in 2012. Available at http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
  • AIOM-AIRTUM. I numeri del cancro in Italia 2013. Available at http://www.registri-tumori.it/cms/it/node/2888
  • AIRTUM-ITACAN: Tumori in Italia, Versione 2.0. Associazione Italiana dei Registri Tumori. Available at http://www.registri-tumori.it
  • Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306: 737-45; http://dx.doi.org/10.1001/jama.2011.1142
  • AIOM. Linee guida Carcinoma della vescica. Edizione 2013
  • Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with Stage Ta T1 bladder cancer using EORTC Risk tables. Eur Urol 2006; 49: 466-5; discussion 475-7
  • Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-4; http://dx.doi.org/10.1016/S0022-5347(05)67280-1
  • Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75
  • Fradet Y, Grossman HB, Gomella L, et al.; PC B302/01 Study Group. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007; 178: 68-73; http://dx.doi.org/10.1016/j.juro.2007.03.028
  • Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 1907-13; http://dx.doi.org/10.1016/j.juro.2010.06.148
  • Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005; 174: 862-6; http://dx.doi.org/10.1097/01.ju.0000169257.19841.2a
  • Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012; 188: 58-62; http://dx.doi.org/10.1016/j.juro.2012.03.007
  • Expert Opinion of Prof. Giario Conti, director of Urology Division at Sant’Anna Hospital, Como
  • Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013; 64: 846-54; http://dx.doi.org/10.1016/j.eururo.2013.03.059
  • Demo Istat.it. Available at http://demo.istat.it/index.html
  • von der Maase H, Sengelov L, Roberts JT, et al. Long term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, cinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8; http://dx.doi.org/10.1200/JCO.2005.07.757
  • EQ-5D™. Available at http://www.euroqol.org/
  • Kulkarni GS, Finelli A, Fleshner NE, et al. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007; 4: e284; http://dx.doi.org/10.1371/journal.pmed.0040284
  • NHS reference costs guidance for 2011-2012. Available at https://www.gov.uk/government/publications/reference-costs-guidance-for-2011-12
  • KARL STORZ Gmbh&Co. Data
  • NHS Technology Adoption Centre (NTAC). The Cost Impact of Implementing Photodynamic Diagnosis of Non-Muscle Invasive Bladder Cancer in England. Final Report, 2011
  • Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari. PharmacoEconomics. Italian Research Articles 2009; 11: 83-93
  • Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 4-34; http://dx.doi.org/10.1016/j.urology.2005.07.062
  • Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Lyon: IARC Publications, 2002
  • Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108; http://dx.doi.org/10.3322/canjclin.55.2.74
  • Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009; 27: 295-300; http://dx.doi.org/10.1007/s00345-009-0395-z
  • Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010; 57: 607-14; http://dx.doi.org/10.1016/j.eururo.2010.01.025

Refbacks

  • There are currently no refbacks.




© SEEd srl